Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 991-994

  Lin, Jiang ^a   Wang, Ya li ^a   Qian, Jun ^a   Yao, Dong ming ^a   Zhu, Zhao hui ^a   Qian, Zhen ^a   Xu, Wen rong ^b  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

DDIT3 gene; Methylation; Myelodysplastic syndrome

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CPG ISLANDS; DNA DAMAGE; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TRANSCRIPTION FACTOR CHOP; YOUNG ADULT;

EID: 77953611367     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.003     Document Type: Article

References (35)

1. Valent P., Horney H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
2. Hirai H. Molecular pathogenesis of MDS. Int J Hematol 2002, 76:213-221.
3. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3928-3932.
4. Kerbauy D.B., Deeg H.J. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007, 35:1739-1746.
5. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
6. Cilloni D., Messa E., Messa F., Carturan S., Defilippi I., Arruga F., et al. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. Ann N Y Acad Sci 2006, 1089:411-423.
7. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
8. Ma Y., Cui W., Yang J., Qu J., Di C., Amin H.M., et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006, 15:2726-2735.
9. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
10. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genetics 2007, 8:286-298.
11. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138:3-11.
12. Voso M.T., Scardocci A., Guidi F., Zini G., Di Mario A., Pagano L., et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004, 103:698-700.
13. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006, 76:23-32.
14. Lin L., Yao D.M., Qian J., Wang Y.L., Han L.X., Jiang Y.W., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008, 32:1541-1545.
15. Fornace A.J., Nebert D.W., Hollander M.C., Luethy J.D., Papathanasiou M., Fargnoli J., et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989, 9:4196-4203.
16. Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992, 6:439-453.
17. Luethy J.D., Fargnoli J., Park J.S., Fornace A.J., Holbrook N.J. Isolation and characterization of the hamster gadd153 gene. Activation of promoter activity by agents that damage DNA. J Biol Chem 1990, 165:16521-16526.
18. Luethy J.D., Holbrook N.J. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res 1992, 52:5-10.
19. Zinszner H., Kuroda M., Wang X., Batchvarova N., Lightfoot R.T., Remotti H., et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998, 12:982-995.
20. Qian J., Chen Z., Lin J., Wang W., Cen J. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases. Leuk Res 2005, 29:1435-1441.
21. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
22. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
23. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. [Erratum in: Blood 91 (1998), p. 1100].
24. Bruchova H., Borovanova T., Klamova H., Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 2002, 43:1289-1295.
25. Oyadomari S., Takeda K., Takiguchi M., Gotoh T., Matsumoto M., Wada I., et al. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 2001, 98:10845-10850.
26. Wu S.J., Yao M., Chou W.C., Tang J.L., Chen C.Y., Ko B.S., et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006, 135:317-323.
27. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113:1315-1325.
28. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17:1813-1819.
29. Grövdal M., Khan R., Aggerholm A., Antunovic P., Astermark J., Bernell P., et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 2007, 13:7107-7112.
30. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
31. Itzykson R., Fenaux P. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol 2009, 16:77-83.
32. Iwai M., Kiyoi H., Ozeki K., Kinoshita T., Emi N., Ohno R., et al. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2005, 19:1367-1375.
33. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
34. Kantarjian H.M., O'Brien S., Huang X., Garcia-Manero G., Ravandi F., Cortes J., et al. Survival advantage with decitabine chemotherapy in patients with myelodysplastic syndrome. Cancer 2007, 109:1133-1137.
35. Raj K., John A., Ho A., Chronis C., Khan S., Samuel J., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21:1937-1944.